In a report released today, Miki Sogi from Bernstein maintained a Hold rating on Astellas Pharma, with a price target of Yen1,600.00. The company’s shares closed last Friday at $11.10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sogi covers the Healthcare sector, focusing on stocks such as Astellas Pharma, Daiichi Sankyo Company, and Chugai Pharmaceutical Co. According to TipRanks, Sogi has an average return of 3.3% and a 47.83% success rate on recommended stocks.
Currently, the analyst consensus on Astellas Pharma is a Moderate Buy with an average price target of $11.48.
Based on Astellas Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $505.79 billion and a net profit of $68.42 billion. In comparison, last year the company earned a revenue of $473.12 billion and had a net profit of $37.6 billion
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
- Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations
- Pfizer and Astellas Pharma’s Promising Prostate Cancer Study: A Potential Game-Changer?
- Pfizer and Astellas Pharma’s Prostate Cancer Study: A Potential Game-Changer?
- Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
